Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neuroblastoma 5Lymphoma 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Melanoma 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Ganglioneuroblastoma 3Carcinoma, Non-Small-Cell Lung 3Osteosarcoma 2Myelodysplastic Syndromes 2Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Breast Neoplasms 2Uveal Melanoma 1Unilateral Breast Neoplasms 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms 1Medulloblastoma 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Kidney Neoplasms 1

Interventions

sargramostim 1Radiotherapy 1Cyclophosphamide 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Unilateral Breast Neoplasms × Colony-Stimulating Factors × Clear all
NCT03012100 2023-01-13

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Academic and Community Cancer Research United

Phase 2 Active not recruiting
280 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡